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Introduction:Hormonal therapy in endometrial cancer (EC) is used for patients whowish
to preserve fertility and for patients with advanced or recurrent disease in a palliative
setting. First line hormonal therapy consists of treatment with progestins, which has a
response rate of 25% in an unselected population. Treatment with anti-estrogens is an
alternative hormonal therapy option, but there is limited data on the effect and side-effects
of anti-estrogens in EC. Therefore, we performed a systematic review to investigate the
response rate and toxicity of anti-estrogenic therapy in patients with endometrial cancer.
Methods: A systematic search in electronic databases was performed to identify studies
on selective estrogen receptor modulators (SERM) and down-regulators (SERD) and
aromatase inhibitors that reported on response rates (RR) among EC patients. Outcome
in estrogen receptor (ER) positive and negative disease was assessed independently.
Results: Sixteen studies on advanced stage and recurrent EC were included. Ten
studies investigated anti-estrogen monotherapy and seven investigated a combination
of anti-estrogenic drugs with either progestin or targeted treatment. Due to heterogeneity
in patient population, no meta-analysis was performed. The median age of the
patients in the included studies ranged from 61 to 71 years and the proportion of
low grade tumors ranged from 38 to 80%. The RR for tamoxifen ranged from 10
to 53%, for other SERMs and SERDs 9–31%, for aromatase inhibitors from 8 to
9%, for combined tamoxifen/progestin treatment 19–58%, for combined chemo- and
hormonal therapy 43% and for combination of anti-estrogenic treatment with mammalian
target of rapamycin (mTOR) inhibitors 14–31%. Toxicity consisted mainly of nausea
and thrombotic events and was higher in combination therapy of chemotherapy
and hormonal therapy and hormonal therapy and mTOR inhibitors compared to
other therapies.
Conclusion: Tamoxifen or a combination of tamoxifen and progestin should be the
preferred choice when selecting second line hormonal treatment because the RRs are
similar to first line progestin treatment and the toxicity is low. The response can be
optimized by selecting patients with endometrioid tumors and positive estrogen receptor
status, which should be based on a pretreatment biopsy.
Keywords: endometrial cancer, anti-estrogen, tamoxifen, fulvestrant, aromatase inhibitor, review
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INTRODUCTION
Endometrial cancer (EC) is the most common gynecologic
malignancy in the Western world (1). The incidence of EC is
increasing and is expected to rise further in the coming years
(2). The most important risk factors for the development of
EC are related to exogenous or endogenous estrogen exposure,
including: estrogen medication, nulliparity, early menarche, late
menopause, and obesity, which contributes to estrogen exposure
by aromatase dependent conversion of androgen into estrogen
(3–7). In general, two types of EC are identified based on
tumor histology and presumed carcinogenesis. Endometrioid
EC (EEC) represents 80% of EC cases and most EECs are
caused by an excess estrogen exposure that, in the absence
of counteractive effects of progesterone, induces endometrial
proliferation and subsequent endometrial hyperplasia and cancer
(8). Non-endometrioid EC (NEEC) is responsible for 20%
of EC incidence and is assumed to develop independent of
estrogen (8, 9). Standard therapy for EC consists of surgery
followed by adjuvant radio- and/or chemotherapy depending
on final tumor characteristics (10, 11). Hormonal therapy is an
alternative treatment for patients who wish to preserve their
fertility, and for those with metastatic or recurrent disease
without curative options (12). Historically, progestin therapy
has been the most widely applied hormonal treatment and it
is still the preferred choice as first line hormonal therapy (10,
13). In addition to progestins, inhibition of estrogen-induced
proliferation by anti-estrogens is used as an alternative to
progestin treatment in EC (14). Currently used anti-estrogenic
drugs are selective estrogen receptor modulators (SERM) or
down-regulators (SERD) and aromatase inhibitors. SERMs
and SERDs such as tamoxifen and fulvestrant have an anti-
proliferative effect by blocking the estrogen receptor (ER)
through which estrogen effects are mediated. Within the group
of SERMs, tamoxifen has both stimulatory and blocking effects
on ER in the endometrium, while other SERMs like raloxifene
and arzoxifene only block ER (15–17). Fulvestrant, the main
SERD, only has antagonistic effects through down regulation of
ER (18). Aromatase inhibitors like anastrozole, letrozole, and
exemestane, limit the estrogen tumor exposure by aromatase
in fat tissue, especially in postmenopausal women (12). The
use of anti-estrogens is well established in breast cancer, but
up till now, there is limited data on the response rates in EC.
In one systematic review and meta-analysis, first and second
line hormonal therapy in recurrent EC was evaluated, but
the different types of hormonal therapy were not evaluated
separately (19). Two separate reviews presented an overview of
available (pre)clinical evidence on, respectively, fulvestrant and
aromatase inhibitors. Unfortunately, no complete overview of
anti-estrogenic treatment was given (20, 21). As a consequence,
choice for anti-estrogenic drugs as second line hormonal
therapy is based on experience of the treating physician, rather
than on refined and up-to-date clinical data. Therefore, we
performed this systematic review to determine the response
rates and toxicity of anti-estrogenic therapy in patients with
endometrial cancer and to relate it to the response rate of
progestin therapy.
METHODS
Search Strategy
This review was performed in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (22). An electronic search was performed
in the following databases from inception until 3rd of October
2018: Pubmed, Embase, clinicaltrials.gov and Cochrane
database of Systematic Review. The search string included
“endometrial cancer,” outcome measures like “response
rate,” “disease progression,” or “survival” and drug terms
like “estrogen antagonists,” “aromatase inhibitors,” “estrogen
receptor modulators,” “estrogen receptor down-regulator,” and
individual drug names. The full search string is shown in
Supplementary Table 1. Citations of relevant articles and
reviews were manually screened to ensure that no study was
missed and that the search was complete.
Study Selection
Studies were included if they reported on (1) women with
endometrial cancer, who used anti-estrogenic therapy for fertility
preservation or for advanced or recurrent disease. Studies
investigating (2) estrogen receptor modulators, estrogen receptor
down-regulators or aromatase inhibitors were eligible if (3)
clinical outcome was reported. Studies reporting findings on
patients with sarcomas or endometrial stroma sarcomas were
excluded as well as conference papers, reviews and letters to
the editor. Case reports and case series with <10 patients were
excluded. Studies that combined anti-estrogen treatment with
other therapy, i.e., progestins, chemotherapy, or targeted therapy
were included and reviewed separately.
Data Extraction and Quality Assessment
Data from included articles was extracted using data collection
forms with information regarding study design, in- and exclusion
criteria, number of included patients, age, tumor stage and
grade, estrogen (ER) and progesterone receptor status, previous
treatment(s) and complete response (CR), partial response
(PR), stable disease (SD), progressive disease, progression free
survival (PFS), and overall survival (OS) was noted. Additional
information was requested from study authors if necessary.
The quality of each individual study was assessed in five
domains based of the National Institute of Health Quality
Assessment Tool for Case Series Studies (23). Each full-text
article was evaluated independently by three authors (WvW,
JP, and AR) and risk of bias was subsequently discussed in a
consensus meeting.
Outcome Assessment and
Statistical Analyses
The primary outcome was the response rate (RR) to hormonal
therapy and was defined as the proportion of patients with CR
and PR. Other outcomes were the clinical benefit rate (CBR),
which is defined as the proportion of patients with either CR,
PR, or SD and toxicity which is defined as any adverse event
occurring during treatment. Toxicity was ideally evaluated with
a standardized measuring scale including grading of severity.
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FIGURE 1 | Selection of studies for systematic review.
Individual treatment arms of randomized studies were analyzed
separately. RR and CBR are reported for tamoxifen, other
SERMs/SERDs, aromatase inhibitors, combination regimens and
for ER positive and negative tumors separately. The specific
expression of the two ER isoforms (ERα and ERβ) was not
considered. Due to the large heterogeneity in the included
studies, meta-analysis could not be performed. In case it was not
reported in the study, the 95% confidence interval for RR and
CBR was calculated using the normal approximation method of
the binomial confidence interval (24).
RESULTS
The search resulted in identification of 2,592 records. After
removal of duplicates, 2,245 unique records were screened on
title and abstract. For the systematic review, 2,208 records were
excluded, leaving 37 articles for full text evaluation (Figure 1).
A total of 21 articles were excluded from the final analysis
due to: case reports or case series with <10 patients (n = 8),
reports on the same patient cohort (n = 4) or studies that were
outside the scope of the review (n = 6), including studies on
endometrial stroma sarcoma and studies on chemotherapy and
radiotherapy (25–30). Three other studies published between
1983 and 1990 could not be evaluated because the full text articles
were not available (31–33). In addition, nine ongoing studies
were identified (34–42).
Included Studies
Sixteen studies were included in the final systematic review. All
included studies investigated patients with advanced stage and
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TABLE 1 | Bias assessment.
References Blinded
treatment
Robust outcome
assessment
Incomplete
outcome data
Selective
outcome
reporting?
Other problems
that introduced
bias
Any disclosure
reported by the
authors
Total
Bonte et al. (43) Not specified
Rendina et al. (44) Not specified
Quinn and Campbell (46) Not specified
Thigpen et al. (49) Not specified
McMeekin et al. (50) Support and co-author from Lilly
Covens et al. (54) Not specified
Emons et al. (55) Support from Astra Zeneca
Rose et al. (47) Nothing to disclose
Ma et al. (52) Support from Novartis
Lindemann et al. (57) Nothing to disclose
Pandya et al. (48) Not specified
Fiorica et al. (51) Nothing to disclose
Whitney et al. (53) Nothing to disclose
Ayoub et al. (45) Support from ICI Americas Inc.
Fleming et al. (56) Nothing to disclose
Slomovitz et al. (58) Support from Novartis
, Low risk of bias; , High risk of bias.
recurrent EC. Ten studies described the use of monotherapy of
which one reported outcomes on mono- and combined therapy,
resulting in a total of seven studies on combined therapy (43–
58). There were two case series and 14 prospective studies.
Bias was assessed as recommended by the National Institute of
Health on five criteria (blinded treatment arms, robustness of
outcome assessment, completeness of the data, selective outcome
reporting and other biases) (23). Results of bias assessment and
conflict of interest disclosures are shown in Table 1. Blinded
treatment was not performed in any study included in the
systematic review and was therefore regarded as high risk in
all studies. Outcome assessment was performed with objective
and reproducible criteria in all but one study (43). Two studies
had a high risk of bias in three domains and were considered
low quality studies (43, 48). All included studies investigated the
effect of hormonal therapy among patients with advanced or
recurrent EC.
Anti-estrogens as Monotherapy
An overview of the included studies that evaluated anti-estrogens
as monotherapy in advanced and recurrent EC is shown in
Table 2. Four studies investigated the use of tamoxifen, three
studies investigated other SERMs or SERDs and three other
studies reported on the use of aromatase inhibitors. Among all
studies, the median age of included patients ranged from 61 to 71
years, and the proportion of patients with NEEC histology varied
between 8 and 48%.
The overall RR of anti-estrogen monotherapy ranged from 8%
(95% CI: 1–15) to 53% (95% CI: 29–78) among included studies
(Figure 2). For tamoxifen the RR ranged from 10% (95% CI: 6–
18) to 53% (95% CI: 29–78), for the other SERMs and SERDs the
RR varied between 9% (95% CI: 2–17) and 31% (95% CI: 15–51)
and for aromatase inhibitors the RR ranged from 8% (95% CI:
1–15) to 9% (95% CI: 2–25). Results of the RR and CBR of all
individual studies are illustrated in Figure 2.
Toxicity was scored according to a standardized scale in 6 out
of 10 eligible studies. The remaining four studies did not report
toxicity at all [n= 1, (43)] or did not report severity of complaints
[n = 3, (44, 46, 49)] (Table 2). Nausea and thromboses were the
most common side-effects. Thrombotic events were not reported
in studies investigating tamoxifen or arzoxifene. The use of
fulvestrant resulted in thrombosis in 6% of patients. Aromatase
inhibitors resulted in thrombosis in 3–5% of patients.
Anti-estrogens in Combined Therapy
As shown in Table 3, the seven studies included in our analysis
investigated either a combination of progestin and tamoxifen
(four studies), a combination of chemotherapy with progestin
and tamoxifen (one study), or a combination of anti-estrogen
treatment with mammalian target of rapamycin (mTOR)
inhibitors (two studies). Two studies on progestin/tamoxifen
combined daily progestin with tamoxifen while the other two
studies alternated between progestin and tamoxifen or added
progestin to daily tamoxifen only in even weeks.
Among the seven studies, median age ranged from 61 to 70
years, and the proportion of low grade EEC tumors ranged from
38 to 80%. The overall RR of combined therapy ranged from
14% (95% CI: 3–36) to 43% (95% CI: 23–64). For combined
progestin/tamoxifen treatment the RR varied between 19% (95%
Frontiers in Oncology | www.frontiersin.org 4 May 2019 | Volume 9 | Article 359
van Weelden et al. Anti-estrogen Treatment in Endometrial Cancer
T
A
B
L
E
2
|
S
tu
d
y
c
h
a
ra
c
te
ris
tic
s
in
m
o
n
o
th
e
ra
p
y.
R
e
fe
re
n
c
e
s
(b
ia
s
ri
s
k
)
N
◦
D
ru
g
a
n
d
d
o
s
e
S
tu
d
y
ty
p
e
P
o
p
u
la
ti
o
n
P
re
v
io
u
s
tr
e
a
tm
e
n
t
A
g
e
(m
e
d
ia
n
)
H
is
to
lo
g
y
/
g
ra
d
e
R
e
s
p
o
n
s
e
P
F
S
(m
o
n
th
s
)
O
S
(m
o
n
th
s
)
To
x
ic
it
y
T
A
M
O
X
IF
E
N
B
o
n
te
e
t
a
l.
( 4
3
)
(h
ig
h
)
1
7
4
0
m
g
/d
a
y
C
a
se
se
rie
s
S
ta
g
e
III
–I
V
o
r
re
c
u
rr
e
n
t
E
C
U
n
re
sp
o
n
si
ve
to
p
ro
g
e
st
in
R
a
n
g
e
2
6
–7
2
N
o
t
re
p
o
rt
e
d
1
2
%
C
R
4
1
%
P
R
N
o
t
re
p
o
rt
e
d
N
o
t
re
p
o
rt
e
d
N
o
t
re
p
o
rt
e
d
R
e
n
d
in
a
e
t
a
l.
( 4
4
)*
(lo
w
)
4
5
4
0
m
g
/d
a
y
P
ro
sp
e
c
tiv
e
S
ta
g
e
III
–I
V
o
r
re
c
u
rr
e
n
t
E
C
N
o
t
re
p
o
rt
e
d
6
1
8
0
%
g
ra
d
e
1
–2
1
3
%
C
R
2
2
%
P
R
1
8
%
S
D
1
1
.5
1
6
N
o
tr
e
a
tm
e
n
t
in
te
rr
u
p
tio
n
Q
u
in
n
a
n
d
C
a
m
p
b
e
ll
(4
6
)
(lo
w
)
4
9
4
0
m
g
/d
a
y
C
a
se
se
rie
s
S
ta
g
e
III
–I
V
o
r
re
c
u
rr
e
n
t
E
C
U
n
re
sp
o
n
si
ve
to
p
ro
g
e
st
in
6
6
8
4
%
E
E
C
8
%
N
E
E
C
3
7
%
g
ra
d
e
1
–2
1
2
%
C
R
8
%
P
R
0
%
S
D
N
o
t
re
p
o
rt
e
d
6
–3
4
d
e
p
e
n
d
in
g
o
n
re
sp
o
n
se
N
a
u
se
a
(1
6
%
)
T
h
ig
p
e
n
e
t
a
l.
( 4
9
)
(lo
w
)
6
8
4
0
m
g
/d
a
y
P
ro
sp
e
c
tiv
e
S
ta
g
e
III
–I
V
o
r
re
c
u
rr
e
n
t
E
C
N
o
p
rio
r
th
e
ra
p
y
8
7
%
>
6
0
y
5
6
%
E
E
C
4
4
%
N
E
E
C
4
%
C
R
6
%
P
R
1
.9
8
.8
N
a
u
se
a
(6
%
)
O
T
H
E
R
S
E
R
M
/S
E
R
D
M
c
M
e
e
ki
n
e
t
a
l.
( 5
0
)
(lo
w
)
2
9
A
rz
o
xi
fe
n
e
2
0
m
g
/d
a
y
P
ro
sp
e
c
tiv
e
S
ta
g
e
III
–I
V
o
r
re
c
u
rr
e
n
t
E
C
E
R
o
r
P
R
+
o
r
g
r1
/2
(if
E
R
/P
R
u
n
kn
o
w
n
)
P
ro
g
e
st
in
st
o
p
p
e
d
>
3
w
e
e
ks
N
o
e
a
rli
e
r
c
h
e
m
o
th
e
ra
p
y
6
6
1
0
0
%
E
E
C
7
4
%
g
ra
d
e
1
–2
3
%
C
R
2
8
%
P
R
7
%
S
D
3
.7
N
o
t
re
p
o
rt
e
d
N
o
g
ra
d
e
3
–4
to
xi
c
ity
C
o
ve
n
s
e
t
a
l.
( 5
4
)
(lo
w
)
5
3
F
u
lv
e
st
ra
n
t
2
5
0
m
g
IM
/4
w
e
e
k
P
ro
sp
e
c
tiv
e
S
ta
g
e
III
–I
V
o
r
re
c
u
rr
e
n
t
E
C
N
o
p
rio
r
h
o
rm
o
n
a
l
th
e
ra
p
y
7
0
%
>
6
0
y
6
6
%
E
E
C
2
3
%
N
E
E
C
4
9
%
g
ra
d
e
1
–2
2
%
C
R
8
%
P
R
2
5
%
S
D
2
E
R
+
:
2
6
E
R
–:
9
G
ra
d
e
3
–4
:
T
h
ro
m
b
o
si
s
(8
%
)
E
m
o
n
s
e
t
a
l.
( 5
5
)
(lo
w
)
3
5
F
u
lv
e
st
ra
n
t
2
5
0
m
g
IM
/4
w
e
e
k
P
ro
sp
e
c
tiv
e
S
ta
g
e
IV
B
o
r
re
c
u
rr
e
n
t
E
C
,
E
R
o
r
P
R
+
o
r
u
n
kn
o
w
n
N
o
p
rio
r
h
o
rm
o
n
a
l
th
e
ra
p
y
7
0
7
1
%
E
E
C
2
6
%
N
E
E
C
6
9
%
g
ra
d
e
1
–2
0
%
C
R
1
1
%
P
R
2
3
%
S
D
2
.3
1
3
.2
G
ra
d
e
3
–4
:
P
u
lm
o
n
a
ry
e
m
b
o
lis
m
(3
%
)
N
a
u
se
a
(6
%
)
A
R
O
M
A
T
A
S
E
IN
H
IB
IT
O
R
R
o
se
e
t
a
l.
(4
7
)
(lo
w
)
2
3
A
n
a
st
ro
zo
le
1
m
g
/d
a
y
P
ro
sp
e
c
tiv
e
S
ta
g
e
III
–I
V
o
r
re
c
u
rr
e
n
t
E
C
M
a
xi
m
u
m
1
p
rio
r
h
o
rm
o
n
a
lt
h
e
ra
p
y
N
o
p
rio
r
c
h
e
m
o
th
e
ra
p
y
8
3
%
>
6
0
5
2
%
E
E
C
4
8
%
N
E
E
C
3
9
%
g
ra
d
e
1
–2
9
%
P
R
9
%
S
D
1
6
G
ra
d
e
3
–4
:
P
u
lm
o
n
a
ry
e
m
b
o
lis
m
(4
%
)
M
a
e
t
a
l.
( 5
2
)
(lo
w
)
3
2
L
e
tr
o
zo
le
2
.5
m
g
/d
a
y
P
ro
sp
e
c
tiv
e
S
ta
g
e
IV
o
r
re
c
u
rr
e
n
t
E
C
P
ro
g
e
st
in
th
e
ra
p
y
a
llo
w
e
d
N
o
e
a
rli
e
r
c
h
e
m
o
.
7
1
N
o
t
re
p
o
rt
e
d
3
%
C
R
6
%
P
R
3
4
%
S
D
N
o
t
re
p
o
rt
e
d
N
R
G
ra
d
e
3
d
e
-p
re
ss
io
n
(3
%
);
th
ro
m
b
o
si
s
(3
%
)
L
in
d
e
m
a
n
n
e
t
a
l.
( 5
7
)
(lo
w
)
5
1
E
xa
m
e
st
a
n
e
2
5
m
g
/d
a
y
P
ro
sp
e
c
tiv
e
S
ta
g
e
III
–I
V
o
r
re
c
u
rr
e
n
t
E
C
,
N
o
h
o
rm
o
n
a
lo
r
c
h
e
m
o
th
e
ra
p
y
6
9
6
1
%
g
ra
d
e
1
–2
5
%
C
R
5
%
P
R
2
0
%
S
D
3
.1
1
0
.9
G
ra
d
e
3
–4
:
A
n
o
re
xi
a
(4
%
)
T
h
ro
m
b
o
si
s
(6
%
)
A
n
e
m
ia
(5
5
%
)
*C
o
n
s
e
c
u
ti
ve
p
ri
m
a
ry
a
n
d
c
o
m
b
in
e
d
h
o
rm
o
n
a
lt
h
e
ra
p
y.
IM
,
in
tr
a
m
u
s
c
u
la
r
a
d
m
in
is
tr
a
ti
o
n
;
E
C
,
e
n
d
o
m
e
tr
ia
lc
a
n
c
e
r;
E
E
C
,
e
n
d
o
m
e
tr
io
id
e
n
d
o
m
e
tr
ia
lc
a
n
c
e
r;
N
E
E
C
,
n
o
n
e
n
d
o
m
e
tr
io
id
e
n
d
o
m
e
tr
ia
lc
a
n
c
e
r;
C
R
,
c
o
m
p
le
te
re
s
p
o
n
s
e
;
P
R
,
p
a
rt
ia
l
re
s
p
o
n
s
e
;
S
D
,
s
ta
b
le
d
is
e
a
s
e
.
Frontiers in Oncology | www.frontiersin.org 5 May 2019 | Volume 9 | Article 359
van Weelden et al. Anti-estrogen Treatment in Endometrial Cancer
FIGURE 2 | Response and clinical benefit rate of monotherapy. The response and clinical benefit rate are shown with 95% confidence intervals between the error
bars. Response rate is defined as the proportion of patients with complete and partial response. The clinical benefit rate is defined as the proportion of patients with
either complete response partial response or stable disease.
CI: 7–31) and 37% (95% CI: 27–47), for chemotherapy with
progestin/tamoxifen the RR was 43% (95% CI: 23–64) and
for combination therapy of hormonal treatment and mTOR
inhibitor the RR ranged from 14% (95% CI: 3–36) to 31% (95%
CI: 17–49) (Figure 3).
Toxicity was scored according to a standardized scale in five
out of seven studies. Thrombosis occurred in 2% of patients with
daily tamoxifen and progestin in even weeks only and in 9%
of patients who alternated tamoxifen with progestins (51, 53).
Chemotherapy and progestin/tamoxifen resulted in moderate to
severe hematologic or gastro-intestinal toxicity in 14 and 12%
of the patients (45). Seventy-five percent of patients received the
optimal treatment dose. The combination of the mTOR inhibitor
temsirolimus with progestin and tamoxifen resulted in serious
thrombotic events in 43% of the patients, causing a premature
stop to accrual in this study (56). The study that combined
everolimus and letrozole reported grade 3–4 fatigue in 11% and
nausea or vomiting in 6% of the patients (58). No thrombosis
was reported. Thirty-two percent of patients required a dose
reduction because of side effects, but no patient had to stop
treatment due to toxicity.
Effect According to ER Status
Among all included studies, six investigated RR and/or CBR for
patients with ER positive and ER negative tumors separately
(Table 4). Tumor tissue used for ER analysis was taken either
before start of hormonal therapy, from the primary tumor or
from the recurrence. Immunohistochemical analysis for ER was
performed using a staining-intensity index in most studies with
different cutoff values, although two studies dichotomized ER
status based on percentage of positive tumor cells. RR in ER
positive patients ranged from 10% (95% CI: 1–19) to 47% (95%
CI: 25–70) and RR in ER negative patients was 0% in all but
one study. The highest RRs were found in studies that based ER
positivity on tumor samples taken from the metastatic site before
start of hormonal therapy. CBR ranged from 35% (95% CI: 20–
50) to 59% (95% CI: 39–80) in ER positive to 0 to 18% (95% CI:
2–34) in ER negative disease.
DISCUSSION
In this systematic review, we have outlined the effect of selective
estrogen receptor modulators (SERM), down-regulators (SERD)
and aromatase inhibitors in patients with advanced stage and
recurrent endometrial cancer (EC). None of the included studies
investigated patients with a wish to preserve fertility indicating
that there is a lack of evidence for anti-estrogenic treatment in
this population. Among studies on advanced stage and recurrent
EC, comparison between different types of anti-estrogenic drugs
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FIGURE 3 | Response and clinical benefit rate of combined treatment. The response and clinical benefit rate are shown with 95% confidence intervals between the
error bars. Response rate is defined as the proportion of patients with complete and partial response. The clinical benefit rate is defined as the proportion of patients
with either complete response partial response or stable disease.
was challenging because of the lack of randomized studies and
differences in patient and tumor characteristics. The investigated
treatments reported similar response rates for all treatments
except for aromatase inhibitors, which had a limited effect in the
investigated populations. Serious side-effects were rare for anti-
estrogens, but occurred more frequently when anti-estrogenic
drugs were combined with chemotherapy or mTOR inhibitors.
The expression of estrogen receptor in the tumor taken prior
to start of treatment was associated with improved response
to anti-estrogens.
The observed RR and CBR differed according to the selected
population, with higher response rates in endometrioid tumors
with positive ER status. Among studies investigating tamoxifen,
Rendina et al reported a RR as high as 36% (95% CI: 22–
50) in patients with predominantly grade 1–2 tumors, whereas
Thigpen found a RR of 10% (95% CI: 6–18) in patients with
NEEC histology in 44% of cases (44, 49). The limited therapeutic
response in NEEC reflects the low impact of estrogen in the
carcinogenesis of these tumors (60). The reported tamoxifen
related toxicity was limited to nausea.
As expected, the therapeutic response to anti-estrogens was
higher among EECs, as illustrated by the study of McMeekin
in which a RR of 31% (95% CI: 15–51) to arzoxifene was
reported in a cohort that included only EEC. Despite these
data, arzoxifene was never introduced into clinical practice.
Two studies explored the use of fulvestrant, reporting limited
responses ranging from 9 to 11%. Furthermore, fulvestrant
can only be administered through intramuscular injection
because of low oral bioavailability, which complicates the clinical
implementation of this drug in a palliative setting. Aromatase
inhibitors were shown to have only limited response rate in the
investigated populations. Thus, aromatase inhibitors should not
be a first choice when selecting anti-estrogenic therapy for EC. As
aromatization of androgens into estrogen occurs predominantly
in fat tissue, patients with obesity might represent a subgroup of
EC patients in which aromatase inhibitors can be more effective.
However, this hypothesis has not been tested in EC patients
and studies in breast cancer do not show superior results of
aromatase inhibitors compared to other hormonal treatments in
obese patients (61).
Out of the four studies investigating combined treatment of
tamoxifen and progestin, three studies enrolled a comparable
patient population and reported a RR ranging from 19 to
27%. Also considering that serious toxicity occurred in just
2–5% of the included patients, the use of tamoxifen combined
with progestins is an attractive treatment regimen. The
addition of progestin and tamoxifen to chemotherapy was
evaluated by one study, which reported a higher RR for the
combination compared to chemotherapy alone. However,
the applied chemotherapy regimen in this study is no longer
in use in EC and no studies that combined anti-estrogenic
therapy with currently used chemotherapeutic drugs have
been performed (62). The combination of hormonal therapy
with an mTOR inhibitor did not result in superior RRs
compared with other anti-estrogenic treatments. Toxicity
remains an important concern, especially for the combination
of temsirolimus with alternating treatment with progestin and
tamoxifen. Interestingly, the combination of letrozole with
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TABLE 4 | Overall response and clinical benefit rate according to estrogen receptor status.
References N
◦
Type Tumor used for ER
analysis
Type of
immunohistochemical
analysis
Response rate
[% (95% CI)]
Clinical benefit
[% (95% CI)]
ER+ ER– ER+ ER–
Singh et al. (59);
Whitney et al. (53)
46 TMX daily and
MPA in alternating
weeks
Before start of
hormonal therapy
Staining intensity index
with range 0–500
Cutoff 75
47 (25–70) 26 (9–42) Not reported
Covens et al. (54) 53 Fulvestrant Recurrence/metastasis % of positive nuclei
Cutoff 10%
16 (3–29) 0 45 (28–63) 18 (2–34)
Emons et al. (55) 27 Fulvestrant Primary tumor NR 11 (0–23) 0 Not reported
Lindemann et al.
(57)
51 Examestane Primary tumor or
recurrence
Staining intensity index
Cutoff: high intensity
10% of nuclei
10 (1–19) 0 35 (20–50) 0
Fleming et al. (56) 20 Temsirolimus and
alternating MA or
TMX
Primary tumor Any level of staining 13 (0–31) 0 Not reported
Slomovitz et al.
(58)
30 Everolimus and
letrozole
Primary tumor or
recurrence
Staining intensity index
range 0–8
Cutoff: 3
Not reported 59 (39–80) 13 (0–35)
MPA, medroxyprogesterone-acetate; TMX, tamoxifen; MA, megestrol acetate.
everolimus was less toxic. A recent GOG study presented
at the SGO meeting 2018 showed similar RRs and adverse
events for letrozole/everolimus and progestin/tamoxifen (63).
Upon validation, this regimen could be an alternative to
progestin/tamoxifen. Further investigation into molecular
alterations that lead to resistance to hormonal therapy might also
provide us with improved individualized combination treatment
for these patients (64).
In summary, treatment with tamoxifen or combined
treatment of tamoxifen and progestin are currently the best
options in anti-estrogen therapy, because of similar or higher
RR when compared to other treatments and limited toxicity.
Preferably, patients with ER positive tumor and endometrioid
histology should be selected for anti-estrogen therapy in order to
optimize the chance of response.
Whether combined tamoxifen/progestin results in improved
response when compared to progestins, has unfortunately not
been studied in a randomized trial. The only study that
randomized between progestin and progestin with tamoxifen
was a low quality study that stopped the progestin arm
prematurely due to poor accrual (48). However, several good
quality studies reported an average response rate of 25% to
progestin in an unselected population, which is similar to
the responses to tamoxifen and progestin/tamoxifen found
in this review (65, 66). The rationale for adding tamoxifen
to progestin is to counteract the down regulation of the
progesterone receptor that is induced by progestin treatment in
order to prolong the duration of response (67, 68). Different
combinations of progestin and tamoxifen have been explored.
One option is to start progestin monotherapy and add or
replace progestin by tamoxifen upon progression, as shown by
two studies among progestin unresponsive patients (43, 44).
Alternatively, combined treatment of tamoxifen with progestin
or alternating treatment can be applied. From the reported
RR in our study, it is not possible to define which regimen
is superior.
Immunohistochemical expression of ER was evaluated by
the studies included in this review using different methods and
cutoffs for positivity. One study defined an optimal cutoff based
on a staining intensity index, but even among ER negative
patients, a high response rate of 26% was observed suggesting
that differentiation between ER positive and ER negative can
still be optimized (59). Future studies on this topic would
ideally result in a test that can be used for all types of stored
and fresh EC tissues and will be adopted worldwide. Most
studies used primary tumor tissue for ER analysis. Yet, primary
tumor and metastases are not comparable due to changes in
the tumor caused by intercurrent therapy and the metastatic
process itself (69–71). Therefore, it is essential that tumor tissue
is obtained directly before start of hormonal therapy to relate
receptor status to response. In case tumor tissue cannot be
procured, non-invasive visualization of estrogen receptor status
on a PET scan with an estrogen tracer might be an alternative
approach (72, 73).
While the strengths of this review include the systematic
approach and the quality assessment for eligible studies,
there are some limitations to be addressed. First, systematic
reviews are based on published data, and may therefore be
biased toward selective reporting of positive results. Although
we have tried to improve the quality by excluding case
series with <10 patients, still this limitation should be
taken into account. Second, criteria for response duration
were not consistently used among all studies hampering
proper comparison of outcome. Finally, most of the included
studies evaluated patients with advanced and recurrent EC.
However, both patient groups might differ in patient and
tumor characteristics. Unfortunately, we could not discriminate
in this review between advanced stage and recurrent EC,
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since most studies did not report outcome separately for
both groups.
The effect of anti-estrogens in advanced and recurrent
EC needs further improvement. In our review, the average
response or clinical benefit rates were (far) below 50% and
the effect of anti-estrogen therapy on progression free survival
and overall survival was limited. Therefore, there is a need
for additional biomarkers to improve selection of patients that
benefit most from anti-estrogen hormonal therapy. Currently,
selection for hormonal treatment is mainly based on estrogen and
progesterone receptor status. However, several studies observe
a benefit for patients even in ER negative disease, highlighting
the need for in depth analysis of the intracellular pathway that
is activated upon binding of estrogen to the estrogen receptor
(54, 58, 59). An initial study on this topic has reported promising
results in breast cancer, but so far no research on this topic
has been performed in endometrial cancer (74). Furthermore,
recent studies have shown that proteins involved in intracellular
conversion of inactive estrogens to active estrogens have a
prognostic role in EC (75, 76). These proteins can theoretically
also oppose the effects of hormonal therapy warranting further
research on this topic. Also, combining hormonal therapy
with targeted therapies is an attractive strategy to overcome
resistance to hormonal treatment and is the subject of many
of the ongoing studies (34–36, 38, 39, 64). Finally, new studies
should focus on patients with stable disease instead of complete
or partial response only. Stable disease can be considered of
clinical benefit for patients in a palliative setting especially if
the disease remains stable for several months. Ideally, future
studies would incorporate a predefined period of stable disease
as outcome measure and would report on clinical benefit as
primary outcome, as some of the included studies already
have (57, 58).
CONCLUSION
Treatment with tamoxifen or the combination of tamoxifen
and progestin should be first choice in anti-estrogen therapy
for patients with advanced and recurrent endometrial cancer
because response rates are comparable to first line hormonal
treatment with progestins and toxicity is limited. Therefore, these
therapies are a good second-line hormonal treatment option in
endometrial cancer. Responses to anti-estrogen therapy can be
improved by selecting patients with endometrioid tumors and
positive estrogen receptor status, which should be based on a
pretreatment biopsy.
AUTHOR CONTRIBUTIONS
AR and JP came up with the concept. WvW and AR performed
the search and selected relevant articles. WvW, AR, and JP
performed bias assessment. WvW, LM, JP, and AR interpreted
the data. WvW, AR, and JP wrote the first draft. All authors
contributed to manuscript revision, read and approved the
submitted version.
FUNDING
The study was partly supported by the Dutch Cancer Society
(KWF Kankerbestrijding, www.kwf.nl), contract number UM-
13-5782 granted to AR.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fonc.
2019.00359/full#supplementary-material
REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424.
doi: 10.3322/caac.21492
2. Shaw E, Farris M, McNeil J, Friedenreich C. Obesity and
endometrial cancer. Recent Results Cancer Res. (2016) 208:107–36.
doi: 10.1007/978-3-319-42542-9_7
3. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an
avoidable cause of cancer in Europe. Int J Cancer. (2001) 91:421–30. doi: 10.
1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T
4. Key TJ, Allen NE, Verkasalo PK, Banks E. Energy balance and cancer: the role
of sex hormones. Proc Nutr Soc. (2001) 60:81–9. doi: 10.1079/PNS200068
5. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and
endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers
Prev. (2002) 11:1531–43.
6. Allen NE, Tsilidis KK, Key TJ, Dossus L, Kaaks R, Lund E, et al.
Menopausal hormone therapy and risk of endometrial carcinoma among
postmenopausal women in the European prospective investigation into
cancer and nutrition. Am J Epidemiol. (2010) 172:1394–403. doi: 10.1093/aje/
kwq300
7. Zhao H, Zhou L, Shangguan AJ, Bulun SE. Aromatase expression and
regulation in breast and endometrial cancer. J Mol Endocrinol. (2016) 57:R19–
33. doi: 10.1530/JME-15-0310
8. Ellenson HL, Ronnett BM, Kurman RJ. Precursor lesions of endometrial
carcinoma. In: Kurman RJ, editor. Blaustein’s Pathology of the
Female Genital Tract. New York, NY: Springer (2011). p. 359–91.
doi: 10.1007/978-1-4419-0489-8_8
9. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol
Oncol. (1983) 15:10–7. doi: 10.1016/0090-8258(83)90111-7
10. Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann
J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer:
diagnosis, treatment and follow-up. Int J Gynecol Cancer. (2016) 26:2–30.
doi: 10.1097/IGC.0000000000000609
11. Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri.
Int J Gynaecol Obstet. (2018) 143(Suppl 2):37–50. doi: 10.1002/ijgo.12612
12. Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal
therapy in recurrent endometrial cancer. Int J Women’s Health. (2014) 6:429–
35. doi: 10.2147/IJWH.S40942
13. Kelley RM, Baker WH. Progestational agents in the treatment of
carcinoma of the endometrium. N Engl J Med. (1961) 264:216–22.
doi: 10.1056/NEJM196102022640503
14. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al.
Relevance of breast cancer hormone receptors and other factors to
the efficacy of adjuvant tamoxifen: patient-level meta-analysis of
randomised trials. Lancet. (2011) 378:771–84. doi: 10.1016/S0140-6736(11)
60993-8
15. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ,
et al. Effects of raloxifene on bone mineral density, serum cholesterol
Frontiers in Oncology | www.frontiersin.org 10 May 2019 | Volume 9 | Article 359
van Weelden et al. Anti-estrogen Treatment in Endometrial Cancer
concentrations, and uterine endometrium in postmenopausal women. N Engl
J Med. (1997) 337:1641–7. doi: 10.1056/NEJM199712043372301
16. Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical
spectrum. Endocr Rev. (1999) 20:418–34. doi: 10.1210/edrv.20.3.0371
17. Goldstein SR, Bhattoa HP, Neven P, Cox DA, Dowsett SA, Alam J,
et al. Gynecologic effects of arzoxifene in postmenopausal women
with osteoporosis or low bone mass. Menopause. (2012) 19:41–7.
doi: 10.1097/gme.0b013e318223bbf4
18. Bross PF, Baird A, Chen G, Jee JM, Lostritto RT, Morse DE, et al. Fulvestrant
in postmenopausal women with advanced breast cancer. Clin Cancer Res.
(2003) 9:4309–17.
19. Ethier JL, Desautels DN, Amir E, MacKay H. Is hormonal therapy effective in
advanced endometrial cancer? A systematic review andmeta-analysis.Gynecol
Oncol. (2017) 147:158–66. doi: 10.1016/j.ygyno.2017.07.002
20. Bogliolo S, Gardella B, Dominoni M, Musacchi V, Cassani C, Zanellini F,
et al. Effectiveness of aromatase inhibitors in the treatment of advanced
endometrial adenocarcinoma. Arch Gynecol Obstet. (2016) 293:701–8.
doi: 10.1007/s00404-015-3974-9
21. Bogliolo S, Cassani C, Dominoni M, Orlandini A, Ferrero S, Iacobone AD,
et al. The role of fulvestrant in endometrial cancer. Expert Opin Drug Metab
Toxicol. (2017) 13:537–44. doi: 10.1080/17425255.2016.1244264
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.
(2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097
23. NIH National Heart Lung and Blood Institute. Study Quality Assessment
Tools. Available online at: https://www.nhlbi.nih.gov/health-topics/study-
quality-assessment-tools (accessed October 1, 2018).
24. Wallis S. Binomial confidence intervals and contingency tests: mathematical
fundamentals and the evaluation of alternative methods. J Quant Linguist.
(2013) 20:178–208. doi: 10.1080/09296174.2013.799918
25. Rose PG, Cha SD, Tak WK, Fitzgerald T, Reale F, Hunter RE.
Radiation therapy for surgically proven para-aortic node metastasis in
endometrial carcinoma. Int J Rad Oncol Biol Phys. (1992) 24:229–33.
doi: 10.1016/0360-3016(92)90676-9
26. Pinelli DM, Fiorica JV, Roberts WS, Hoffman MS, Nicosia SV, Cavanagh D.
Chemotherapy plus sequential hormonal therapy for advanced and recurrent
endometrial carcinoma: a phase II study. Gynecol Oncol. (1996) 60:462–7.
doi: 10.1006/gyno.1996.0074
27. Covens A, Brunetto VL, Markman M, Orr JW, Lentz SS, Benda J. Phase
II trial of danazol in advanced, recurrent, or persistent endometrial cancer:
a gynecologic oncology group study. Gynecol Oncol. (2003) 89:470–4.
doi: 10.1016/S0090-8258(03)00149-5
28. Dahhan T, Fons G, Buist MR, ten Kate FJW, van der Velden J. The
efficacy of hormonal treatment for residual or recurrent low-grade
endometrial stromal sarcoma. A retrospective study. Eur J Obstet
Gynecol Reprod Biol. (2009) 144:80–4. doi: 10.1016/j.ejogrb.2009.
02.005
29. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan
JA, et al. Phase 2 trial of aromatase inhibition with letrozole in
patients with uterine leiomyosarcomas expressing estrogen and/or
progesterone receptors. Cancer. (2014) 120:738–43. doi: 10.1002/cncr.
28476
30. Beck TL, Giannakopoulos NV, Rendi MH, Isacson C, Goff BA. Impact
of oophorectomy and hormone suppression in low grade endometrial
stromal sarcoma: a multicenter review. Gynecol Oncol. (2008) 149:297–300.
doi: 10.1016/j.ygyno.2018.03.008
31. Hald I, Salimtschik M, Mouridsen HT. Tamoxifen treatment of advanced
endometrial carcinoma. A phase II study. Eur J Gynaecol Oncol. (1983) 4:83–7.
32. Kline RC, Freedman RS, Jones LA, Atkinson EN. Treatment of recurrent
or metastatic poorly differentiated adenocarcinoma of the endometrium
with tamoxifen and medroxyprogesterone acetate. Cancer Treat. Rep.
(1987) 71:327–8.
33. Horvath G, Stendahl U, Kalling M, Ferno M, Himmelmann A, Hajba A.
Antiestrogenic treatment of advanced and recurrent carcinoma corporis
uteri–a phase II study of toremifene. Anticancer Res. (1990) 10:323–5.
34. Sinai Hospital of Baltimore (2016). Single Arm Trial With Combination
of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or
Refractory or Persistent Ovarian Cancer/Endometrial Cancer.
35. Gynecologic Oncology Group, Novartis Pharmaceuticals. (2018). Everolimus
and Letrozole or Hormonal Therapy to Treat Endometrial Cancer.
36. Centre Leon Berard (2019). Hormone Receptor Positive Endometrial
Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and
Anastrozole (VICTORIA).
37. National Cancer Institute and National Institutes of Health Clinical Center
(2019). Endoxifen in Adults With Hormone Receptor Positive Solid Tumors.
38. ArQule (2020). Open-Label PHASE 1b Study of ARQ 092 in Combination
With Anastrozole.
39. Dana-Farber Cancer Institute, Eli Lilly and Company (2020). A Phase
2 Study of LY3023414 and Abemaciclib With or Without Letrozole in
Endometrial Cancer.
40. National Cancer Institute (2020). Exemestane in Treating Patients With
Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial
Neoplasia or Low Grade Endometrial Cancer.
41. Mayo Clinic and National Cancer Institute (2021). Ribociclib and Letrozole in
Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary
Peritoneal, or Endometrial Cancer.
42. Memorial Sloan Kettering Cancer Center, Eli Lilly and Company (2021).
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant
in Women With Recurrent Endometrial Cancer.
43. Bonte J, Ide P, Billiet G,Wynants P. Tamoxifen as a possible chemotherapeutic
agent in endometrial adenocarcinoma. Gynecol Oncol. (1981) 11:140–61.
doi: 10.1016/S0090-8258(81)80003-0
44. Rendina GM, Donadio C, Fabri M, Mazzoni P, Nazzicone P.
Tamoxifen and medroxyprogesterone therapy for advanced endometrial
carcinoma. Eur J Obstet Gynecol Reprod Biol. (1984) 17:285–91.
doi: 10.1016/0028-2243(84)90071-6
45. Ayoub J, Audet-Lapointe P, Methot Y, Hanley J, Beaulieu R, Chemaly R, et al.
Efficacy of sequential cyclical hormonal therapy in endometrial cancer and
its correlation with steroid hormone receptor status. Gynecol Oncol. (1988)
31:327–37. doi: 10.1016/S0090-8258(88)80012-X
46. Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent
endometrial carcinoma. Gynecol Oncol. (1989) 32:1–3.
doi: 10.1016/0090-8258(89)90839-1
47. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A Phase II trial
of anastrozole in advanced recurrent or persistent endometrial carcinoma:
a gynecologic oncology group study. Gynecol Oncol. (2000) 78:212–6.
doi: 10.1006/gyno.2000.5865
48. Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, et al.
Megestrol and tamoxifen in patients with advanced endometrial cancer: an
Eastern Cooperative Oncology Group study (E4882). Am J Clin Oncol Cancer
Clin Trials. (2001) 24:43–6. doi: 10.1097/00000421-200102000-00007
49. Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen
in the treatment of advanced or recurrent endometrial carcinoma: a
Gynecologic Oncology Group study. J Clin Oncol. (2001) 19:364–7.
doi: 10.1200/JCO.2001.19.2.364
50. McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T, et al.
A phase II trial of arzoxifene, a selective estrogen response modulator, in
patients with recurrent or advanced endometrial cancer. Gynecol Oncol.
(2003) 90:64–9. doi: 10.1016/S0090-8258(03)00203-8
51. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase
II trial of alternating courses of megestrol acetate and tamoxifen in advanced
endometrial carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol.
(2004) 92:10–4. doi: 10.1016/j.ygyno.2003.11.008
52. Ma BBY, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, et al.
The activity of letrozole in patients with advanced or recurrent endometrial
cancer and correlation with biological markers - A study of the National
Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. (2004)
14:650–8. doi: 10.1111/j.1048-891X.2004.14419.x
53. Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK,
et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in
advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Gynecol Oncol. (2004) 92:4–9. doi: 10.1016/j.ygyno.2003.09.018
54. Covens AL, Filiaci V, Gersell D, Lutman CV, Bonebrake A, Lee YC. Phase
II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a
Gynecologic Oncology Group study. Gynecol Oncol. (2011) 120:185–8.
doi: 10.1016/j.ygyno.2010.10.015
Frontiers in Oncology | www.frontiersin.org 11 May 2019 | Volume 9 | Article 359
van Weelden et al. Anti-estrogen Treatment in Endometrial Cancer
55. Emons G, Gunthert A, Thiel FC, Camara O, Strauss HG, Breitbach
GP, et al. Phase II study of fulvestrant 250 mg/month in patients
with recurrent or metastatic endometrial cancer: a study of the
Arbeitsgemeinschaft Gynakologische Onkologie. Gynecol Oncol. (2013)
129:495–9. doi: 10.1016/j.ygyno.2013.02.039
56. Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M,
et al. Temsirolimus with or without megestrol acetate and tamoxifen for
endometrial cancer: a gynecologic oncology group study. Gynecol Oncol.
(2014) 132:585–92. doi: 10.1016/j.ygyno.2014.01.015
57. Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB,
Aavall-Lundqvist E, et al. Examestane in advanced or recurrent endometrial
carcinoma: a prospective phase II study by the Nordic Society of Gynecologic
Oncology (NSGO). BMC Cancer. (2014) 14:68. doi: 10.1186/1471-2407-14-68
58. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski
M, et al. Phase II study of everolimus and letrozole in patients
with recurrent endometrial carcinoma. J Clin Oncol. (2015) 33:930–6.
doi: 10.1200/JCO.2014.58.3401
59. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. (2007). Relationship of estrogen
and progesterone receptors to clinical outcome in metastatic endometrial
carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 106:325–33.
doi: 10.1016/j.ygyno.2007.03.042
60. Lax SF. Molecular genetic pathways in various types of endometrial
carcinoma: from a phenotypical to a molecular-based classification. Virchows
Arch. (2004) 444:213–23. doi: 10.1007/s00428-003-0947-3
61. Slowik A, Fraczek PA, Krzemieniecki K. Body mass index and
aromatase inhibitors: a step forward in individualizing therapy for
breast cancer patients? Expert Rev Anticancer Ther. (2016) 16:759–66.
doi: 10.1080/14737140.2016.1191949
62. Bestvina CM, Fleming GF. Chemotherapy for endometrial cancer in
adjuvant and advanced disease settings. Oncologist. (2016) 21:1250–9.
doi: 10.1634/theoncologist.2016-0062
63. Slomovitz BM, Filiaci VL, Coleman RL, Walker JL, Fleury AC, Holman LL,
et al. (2018). GOG 3007, a randomized phase II (RP2) trial of everolimus and
letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen,
PT) in womenwith advanced, persistent or recurrence endometrial carcinoma
(EC): a GOG Foundation study. In: SGO 49th Annual Meeting on Women’s
Cancer. New Orleans, LA. doi: 10.1016/j.ygyno.2018.04.012
64. MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A,
et al. Moving forward with actionable therapeutic targets and opportunities in
endometrial cancer: NCI clinical trials planning meeting report on identifying
key genes and molecular pathways for targeted endometrial cancer trials.
Oncotarget. (2017) 8:84579–94. doi: 10.18632/oncotarget.19961
65. Lentz SS, BradyMF,Major FJ, Reid GC, Soper JT. High-dose megestrol acetate
in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology
Group study. J Clin Oncol. (1996) 14:357–61. doi: 10.1200/JCO.1996.14.2.357
66. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD,
Manetta A, et al. Oral medroxyprogesterone acetate in the treatment
of advanced or recurrent endometrial carcinoma: a dose-response study
by the Gynecologic Oncology Group. J Clin Oncol. (1999) 17:1736–44.
doi: 10.1200/JCO.1999.17.6.1736
67. Mortel R, Levy C, Wolff JP, Nicolas JC, Robel P, Baulieu EE. Female sex
steroid receptors in postmenopausal endometrial carcinoma and biochemical
response to an antiestrogen. Cancer Res. (1981) 41:1140–7.
68. Carlson JA Jr., Allegra JC, Day TG Jr., Wittliff JL. Tamoxifen and
endometrial carcinoma: alterations in estrogen and progesterone receptors in
untreated patients and combination hormonal therapy in advanced neoplasia.
Am J Obstet Gynecol. (1984) 149:149–53. doi: 10.1016/0002-9378(84)
90187-X
69. Tacca O, Penault-Llorca F, Abrial C,Mouret-ReynierMA, Raoelfils I, Durando
X, et al. Changes in and prognostic value of hormone receptor status in a series
of operable breast cancer patients treated with neoadjuvant chemotherapy.
Oncologist. (2007) 12:636–43. doi: 10.1634/theoncologist.12-6-636
70. Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, Akslen
L, et al. Evolution in endometrial cancer: evidence from an
immunohistochemical study. Int J Gynecol Cancer. (2011) 21:316–22.
doi: 10.1097/IGC.0b013e31820575f5
71. Bartosch C, Monteiro-Reis S, Vieira R, Pereira A, Rodrigues M,
Jeronimo C, et al. Endometrial endometrioid carcinoma metastases
show decreased ER-Alpha and PR-A expression compared to matched
primary tumors. PLoS ONE. (2015) 10:e0134969. doi: 10.1371/journal.pone.
0134969
72. Tsujikawa T, Yoshida Y, Kiyono Y, Kurokawa T, Kudo T, Fujibayashi Y, et al.
Functional oestrogen receptor alpha imaging in endometrial carcinoma using
16alpha-[(1)(8)F]fluoro-17beta-oestradiol PET. Eur J Nucl Med Mol Imaging.
(2011) 38:37–45. doi: 10.1007/s00259-010-1589-8
73. van Kruchten M, de Vries EG, Brown M, de Vries EF, Glaudemans
AW, Dierckx RA, et al. PET imaging of oestrogen receptors in
patients with breast cancer. Lancet Oncol. (2013) 14:e465–75.
doi: 10.1016/S1470-2045(13)70292-4
74. Verhaegh W, van Ooijen H, Inda MA, Hatzis P, Versteeg R, Smid
M, et al. Selection of personalized patient therapy through the use
of knowledge-based computational models that identify tumor-
driving signal transduction pathways. Cancer Res. (2014) 74:2936–45.
doi: 10.1158/0008-5472.CAN-13-2515
75. Cornel KM, Kruitwagen RF, Delvoux B, Visconti L, Van de Vijver KK,
Day JM, et al. Overexpression of 17beta-hydroxysteroid dehydrogenase
type 1 increases the exposure of endometrial cancer to 17beta-
estradiol. J Clin Endocrinol Metab. (2012) 97:E591–601. doi: 10.1210/jc.
2011-2994
76. Cornel KM, Krakstad C, Delvoux B, Xanthoulea S, Jori B, Bongers
MY, et al. High mRNA levels of 17beta-hydroxysteroid dehydrogenase
type 1 correlate with poor prognosis in endometrial cancer.
Mol Cell Endocrinol. (2017) 442:51–7. doi: 10.1016/j.mce.2016.
11.030
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 van Weelden, Massuger, ENITEC, Pijnenborg and Romano. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Oncology | www.frontiersin.org 12 May 2019 | Volume 9 | Article 359
